Gamma d-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it

ABSTRACT

A γd-Crystalline form of ivabradine hydrochloride of formula (I): 
                         
characterised by its powder X-ray diffraction data.
 
     Medicinal products containing the same which are useful as bradycardics.

The present invention relates to the new γd-crystalline form ofivabradine hydrochloride of formula (I), to a process for itspreparation and to pharmaceutical compositions containing it.

Ivabradine, and addition salts thereof with a pharmaceuticallyacceptable acid, and more especially its hydrochloride, have veryvaluable pharmacological and therapeutic properties, especiallybradycardic properties, making those compounds useful in the treatmentor prevention of various clinical situations of myocardial ischaemiasuch as angina pectoris, myocardial infarct and associated rhythmdisturbances, and also in various pathologies involving rhythmdisturbances, especially supraventricular rhythm disturbances, and inheart failure.

The preparation and therapeutic use of ivabradine and addition saltsthereof with a pharmaceutically acceptable acid, and more especially itshydrochloride, have been described in the European patent specificationEP 0 534 859.

In view of the pharmaceutical value of this compound, it has been ofprime importance to obtain it with excellent purity. It has also beenimportant to be able to synthesise it by means of a process that canreadily be converted to the industrial scale, especially in a form thatallows rapid filtration and drying. Finally, that form had to beperfectly reproducible, easily formulated and sufficiently stable toallow its storage for long periods without particular requirements fortemperature, light or oxygen level.

The patent specification EP 0 534 859 describes a synthesis process forivabradine and its hydrochloride. However, that document does notspecify the conditions for obtaining ivabradine in a form that exhibitsthose characteristics in a reproducible manner.

The Applicant has now found that a particular salt of ivabradine, thehydrochloride, can be obtained in a crystalline form that is welldefined and that exhibits valuable characteristics of stability andprocessability.

More specifically, the present invention relates to the γd-crystallineform of ivabradine hydrochloride, which is characterised by thefollowing powder X-ray diffraction diagram measured using a PANalyticalX'Pert Pro diffractometer together with an X'Celerator detector andexpressed in terms of ray position (Bragg's angle 2 theta, expressed indegrees), ray height (expressed in counts), ray area (expressed incounts x degrees), ray width at half-height (“FWHM”, expressed indegrees) and interplanar distance d (expressed in Å):

Angle Area 2 theta Height (counts × FWHM Interplanar Ray no. (degrees)(counts) degrees) (degrees) distance (Å) 1 4.3 1077 124 0.1171 20.633 26.9 132 70 0.5353 12.787 3 8.4 269 35 0.1338 10.482 4 10.6 322 26 0.08368.310 5 11.9 733 97 0.1338 7.414 6 12.5 1406 278 0.2007 7.069 7 13.42975 442 0.1506 6.619 8 14.4 825 122 0.1506 6.134 9 15.8 1036 205 0.20075.598 10 16.3 540 107 0.2007 5.450 11 16.9 1007 183 0.184 5.233 12 17.8499 58 0.1171 4.978 13 18.9 1062 140 0.1338 4.686 14 19.8 570 85 0.15064.485 15 20.2 549 63 0.1171 4.399 16 20.9 2565 635 0.2509 4.241 17 21.6531 105 0.2007 4.104 18 22.3 213 35 0.1673 3.981 19 23.4 278 27 0.10043.807 20 24.1 1404 185 0.1338 3.694 21 24.4 1526 176 0.1171 3.650 2224.8 676 100 0.1506 3.591 23 25.4 702 139 0.2007 3.504 24 26.2 1737 4010.2342 3.403 25 26.8 258 51 0.2007 3.331 26 27.2 182 24 0.1338 3.282 2727.9 838 249 0.3011 3.193 28 29.1 152 20 0.1338 3.071

The invention relates also to a process for the preparation of theγd-crystalline form of ivabradine hydrochloride, which process ischaracterised in that a mixture of ivabradine hydrochloride and2-ethoxyethanol, a mixture of ivabradine hydrochloride, 2-ethoxyethanoland water, or a mixture of ivabradine hydrochloride, ethanol and wateris heated until dissolution is complete and is then cooled untilcrystallisation is complete, and the crystals obtained are collected byfiltration and dehydrated.

-   -   In the crystallisation process according to the invention it is        possible to use ivabradine hydrochloride obtained by any        process, for example ivabradine hydrochloride obtained by the        preparation process described in patent specification EP 0 534        859.    -   The solution may advantageously be seeded during the cooling        step.

The invention relates also to pharmaceutical compositions comprising asactive ingredient the γd-crystalline form of ivabradine hydrochloridetogether with one or more appropriate, inert, non-toxic excipients.Among the pharmaceutical compositions according to the invention, theremay be mentioned more especially those that are suitable for oral,parenteral (intravenous or subcutaneous) or nasal administration,tablets or dragées, sublingual tablets, gelatin capsules, lozenges,suppositories, creams, ointments, dermal gels, injectable preparations,drinkable suspensions.

The useful dosage can be varied according to the nature and severity ofthe disorder, the administration route and the age and weight of thepatient. That dosage varies from 1 to 500 mg per day in one or moreadministrations.

The following Examples illustrate the invention.

The X-ray powder diffraction spectrum was measured under the followingexperimental conditions:

-   PANalytical X'Pert Pro diffractometer, X'Celerator detector,    temperature-regulated chamber,-   voltage 45 kV, intensity 40 mA,-   mounting θ-θ,-   nickel (Kβ) filter,-   incident-beam and diffracted-beam Soller slit: 0.04 rad,-   fixed angle of divergence slits: ⅛°,-   mask: 10 mm,-   antiscatter slit: ¼°,-   measurement mode: continuous from 3° to 30°, in increments of    0.017°,-   measurement time per step: 19.7 s,-   total time: 4 min 32 s,-   measurement speed: 0.108°/s,-   measurement temperature: ambient.

EXAMPLE 1 γd-Crystalline Form of Ivabradine Hydrochloride

40 ml of 2-ethoxyethanol are preheated to 80° C., and then 8.4 g ofivabradine hydrochloride obtained according to the process described inthe patent specification EP 0 534 859 are added in portions, withstirring, and the mixture is heated at 80° C. until dissolution iscomplete. After returning to ambient temperature, the solution is storedfor 8 days, and then the crystals formed are collected by filtration andrinsed with cyclohexane.

The product thereby obtained is dehydrated by progressively heating at arate of 5° C./min up to a temperature of 80° C.

X-Ray Powder Diffraction Diagram:

The X-ray powder diffraction profile (diffraction angles) of the γd-formof ivabradine hydrochloride is given by the significant rays collated inthe following table:

Angle Area 2 theta Height (counts × FWHM Interplanar Ray no. (degrees)(counts) degrees) (degrees) distance (Å) 1 4.3 1077 124 0.1171 20.633 26.9 132 70 0.5353 12.787 3 8.4 269 35 0.1338 10.482 4 10.6 322 26 0.08368.310 5 11.9 733 97 0.1338 7.414 6 12.5 1406 278 0.2007 7.069 7 13.42975 442 0.1506 6.619 8 14.4 825 122 0.1506 6.134 9 15.8 1036 205 0.20075.598 10 16.3 540 107 0.2007 5.450 11 16.9 1007 183 0.184 5.233 12 17.8499 58 0.1171 4.978 13 18.9 1062 140 0.1338 4.686 14 19.8 570 85 0.15064.485 15 20.2 549 63 0.1171 4.399 16 20.9 2565 635 0.2509 4.241 17 21.6531 105 0.2007 4.104 18 22.3 213 35 0.1673 3.981 19 23.4 278 27 0.10043.807 20 24.1 1404 185 0.1338 3.694 21 24.4 1526 176 0.1171 3.650 2224.8 676 100 0.1506 3.591 23 25.4 702 139 0.2007 3.504 24 26.2 1737 4010.2342 3.403 25 26.8 258 51 0.2007 3.331 26 27.2 182 24 0.1338 3.282 2727.9 838 249 0.3011 3.193 28 29.1 152 20 0.1338 3.071

EXAMPLE 2 Pharmaceutical Composition

Formula for the preparation of 1000 tablets each containing 5 mg ofivabradine base:

Compound of Example 1 5.39 g   Maize starch 20 g Anhydrous colloidalsilica 0.2 g  Mannitol 63.91 g   PVP 10 g Magnesium stearate 0.5 g 

1. A γd-Crystalline form of ivabradine hydrochloride of formula (I):

having a powder X-ray diffraction diagram exhibiting peaks at 12.5,13.4, 20.9, 24.4 and 26.2 deg 2 theta.
 2. A solid pharmaceuticalcomposition comprising as active ingredient the γd-crystalline form ofivabradine hydrochloride of claim 1, in combination with one or morepharmaceutically acceptable, inert, non-toxic carriers.
 3. A method fortreating a condition selected from angina pectoris, myocardial infarct,and heart failure, such method comprising administering to a human, atherapeutically effective amount of the γd-crystalline form ofivabradine hydrochloride of claim 1.